HCFA (Health Care Financing Administration) Internet disclosure too open for some companies
This article was originally published in Clinica
Executive Summary
The US medical device industry is not uniformly supportive of the Health Care Financing Administration's (HCFA) new attitude of openness. Three companies sent in letters of protest to the agency within 72 hours of the meeting it held recently on proposals to overhaul its Medicare coverage process (see Clinica No 828, p 6), according to Grant Bagley, director of HCFA's coverage and analysis group.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.